Depressive symptoms among adults in 2018-2019 and during the 2020 COVID-19 pandemic in Italy.
Covid-19
Depression
Longitudinal evaluation
Nationally representative study
Post-lockdown
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
received:
27
11
2021
revised:
13
04
2022
accepted:
19
04
2022
pubmed:
27
4
2022
medline:
25
5
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
Restrictions due to Coronavirus disease 2019 (COVID-19) has produced a large number of effects on mental health, which are expected to endure over time. In this study, we assessed depressive symptom levels before the COVID-19 pandemic, from January 2018 to December 2019, and during the pandemic in Italy in 2020. We used the Patient Health Questionnaire-2 (PHQ-2), which is a screening instrument devised to detect probable depression and which has been annually administered in the framework of the Italian Behavioural Risk Factor Surveillance System since 2008. Depressive symptoms were assessed in a sample of 41,362 18-64-year-old adults surveyed in 2018-2019 and in a sample of 14,612 adults surveyed in 2020. The prevalence of depressive symptoms increased from 6.1% (95% CI 5.8%-6.4%) in 2018-2019 to 7.1% (95% CI 5.6%-8.6%) in March-April 2020. It then declined in May-June to 4.4% (95% CI 3.2%-5.5%) but in July-August it once again increased to 8.2% (95% CI 6.0%-10.4%) and, finally, gradually returned above the pre-lockdown level by November-December 2020 (5.9%; 95% CI 4.7%-7.1%). Compared to before the health crisis, during the pandemic, women and individuals with financial difficulties were found to have a significantly higher risk of depressive symptoms while younger, individuals with a higher education and those living in South Italy became increasingly vulnerable. While the average response to the pandemic was one of resilience over time, women and younger individuals were found to be particularly prone to the risk of depressive symptoms, as a result of the pandemic. In future investigations, the risk of individuals living in the South of Italy should also be taken into consideration.
Sections du résumé
BACKGROUND
Restrictions due to Coronavirus disease 2019 (COVID-19) has produced a large number of effects on mental health, which are expected to endure over time. In this study, we assessed depressive symptom levels before the COVID-19 pandemic, from January 2018 to December 2019, and during the pandemic in Italy in 2020.
METHODS
We used the Patient Health Questionnaire-2 (PHQ-2), which is a screening instrument devised to detect probable depression and which has been annually administered in the framework of the Italian Behavioural Risk Factor Surveillance System since 2008. Depressive symptoms were assessed in a sample of 41,362 18-64-year-old adults surveyed in 2018-2019 and in a sample of 14,612 adults surveyed in 2020.
RESULTS
The prevalence of depressive symptoms increased from 6.1% (95% CI 5.8%-6.4%) in 2018-2019 to 7.1% (95% CI 5.6%-8.6%) in March-April 2020. It then declined in May-June to 4.4% (95% CI 3.2%-5.5%) but in July-August it once again increased to 8.2% (95% CI 6.0%-10.4%) and, finally, gradually returned above the pre-lockdown level by November-December 2020 (5.9%; 95% CI 4.7%-7.1%). Compared to before the health crisis, during the pandemic, women and individuals with financial difficulties were found to have a significantly higher risk of depressive symptoms while younger, individuals with a higher education and those living in South Italy became increasingly vulnerable.
CONCLUSIONS
While the average response to the pandemic was one of resilience over time, women and younger individuals were found to be particularly prone to the risk of depressive symptoms, as a result of the pandemic. In future investigations, the risk of individuals living in the South of Italy should also be taken into consideration.
Identifiants
pubmed: 35472470
pii: S0165-0327(22)00475-X
doi: 10.1016/j.jad.2022.04.131
pmc: PMC9034833
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
J Affect Disord. 2020 Dec 1;277:842-849
pubmed: 33065825
Asian J Psychiatr. 2020 Jun;51:102092
pubmed: 32315963
JAMA. 2020 Jun 9;323(22):2290-2300
pubmed: 32515813
PLoS One. 2020 Apr 16;15(4):e0231924
pubmed: 32298385
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Prev Chronic Dis. 2011 Jan;8(1):A24
pubmed: 21159236
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
BMC Med Res Methodol. 2003 Oct 20;3:21
pubmed: 14567763
J Occup Environ Med. 2021 Sep 1;63(9):e571-e579
pubmed: 34091576
PLoS One. 2021 Jan 7;16(1):e0245057
pubmed: 33411843
J Affect Disord. 2022 Feb 1;298(Pt A):202-208
pubmed: 34732338
Lancet Reg Health Eur. 2021 Mar;2:100020
pubmed: 33870246
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370116
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Lancet Psychiatry. 2021 Jul;8(7):610-619
pubmed: 33965057
Public Health. 2021 Sep;198:218-222
pubmed: 34481278
MMWR Morb Mortal Wkly Rep. 2010 Oct 1;59(38):1229-35
pubmed: 20881934
J Affect Disord. 2021 Sep 1;292:398-404
pubmed: 34139414
J Epidemiol. 2020 Nov 5;30(11):522-528
pubmed: 32963212
Lancet. 2021 Dec 11;398(10317):2193-2206
pubmed: 34695372
Prev Chronic Dis. 2015 Oct 29;12:E183
pubmed: 26513439
J Psychosom Res. 2020 Jun;133:110113
pubmed: 32354463
J Affect Disord. 2021 Jan 1;278:131-135
pubmed: 32956962
Psychol Med. 2018 Jun;48(8):1308-1315
pubmed: 29021005
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Am Psychol. 2020 Jul-Aug;75(5):618-630
pubmed: 32496074
Lancet Psychiatry. 2021 Feb;8(2):141-149
pubmed: 33308420
PLoS One. 2020 May 14;15(5):e0233410
pubmed: 32407409
Brain Behav Immun. 2020 Jul;87:172-176
pubmed: 32405150
Psychol Med. 2020 Nov 13;:1-10
pubmed: 33183370
J Public Health Res. 2021 Oct 06;11(1):
pubmed: 34615342
J Psychiatr Res. 2021 Apr;136:603-609
pubmed: 33138985
Ann Epidemiol. 2014 Apr;24(4):241-5
pubmed: 24461932
JAMA. 2020 Jul 7;324(1):93-94
pubmed: 32492088
Eur Psychiatry. 2020 Sep 28;63(1):e87
pubmed: 32981568
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Asian J Psychiatr. 2020 Jun;51:102076
pubmed: 32334409
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037
Med Sci Monit. 2020 Apr 26;26:e924609
pubmed: 32335579
Lancet Infect Dis. 2020 Aug;20(8):904-905
pubmed: 32738239